gi 5005
Vaccineexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2005 (NCT00124215)
Timeline
Indications
Mechanism of action
- Hepatitis C virus NS3 protease/helicaseImmunity, active
A3EZI9 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gi5005
- gi 5005
- gi-5005
- gi-5005
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00606086 | Phase 2 | Dec 1, 2007 | GlobeImmune |
| NCT00124215 | Phase 1 | Jun 1, 2005 | GlobeImmune |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlobeImmune | For profit | 2 | 2 | 2 | 2005 |
1 organizations
Page 1 / 1